Lugol's solution clinical trials
How each study uses Lugol's solution is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Lugol's solution studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Shandong University (2) · Aristotle University Of Thessaloniki (1) · Xijing Hospital of Digestive Diseases (1) · E-DA Hospital (1)
Studies
Open first, then newest update. How each study uses Lugol's solution is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal DissectionRecruitingNot applicableE-DA HospitalNCT03183115Written as Lugol's Solution (1.5%)
- High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal ChromoendoscopyCompletedNot applicableXijing Hospital of Digestive DiseasesNCT06063941Written as 1% Lugol's iodine solution
- Preoperative Administration of Lugols Solution in Toxic Thyroid Diseases (TD): A Prospective StudyActive, not recruitingNot applicableAristotle University Of ThessalonikiNCT06176976Written as Lugol's iodine solution 5%
- Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine StainingCompletedPhase 2Shandong UniversityNCT03180944Written as 1.2% Lugol's solution
- Different Lugol's Solution Concentration for Image Quality of Esophageal Lesions in Chromoendoscopy With Iodine StainingStatus unknownPhase 4Shandong UniversityNCT03180970Written as 1.2% Lugol's solution
Codes
What other systems call Lugol's solution · ClinicalTrials.gg INT002487
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C010389 | Lugol's solution | Confirmed ClinicalTrials.gov, NLM |
| RxNorm | 1376155 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.